Loading…
Galectin Therapeutics Inc. is projected to rise to $7.37 by 2027, a +82% move from its current price of $4.06. GALT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.84 | $4.06 | $4.29 | -0.04% |
| Jul 15 | $3.75 | $4.06 | $4.39 | -0.09% |
| Jul 16 | $3.68 | $4.05 | $4.47 | -0.13% |
| Jul 17 | $3.62 | $4.05 | $4.53 | -0.17% |
| Jul 18 | $3.58 | $4.05 | $4.59 | -0.22% |
| Jul 19 | $3.53 | $4.05 | $4.64 | -0.26% |
| Jul 20 | $3.49 | $4.05 | $4.69 | -0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.49 | $4.05 | $4.69 | -0.31% |
| Week 2 | $3.27 | $4.04 | $4.97 | -0.61% |
| Week 3 | $3.11 | $4.02 | $5.20 | -0.91% |
| Week 4 | $2.98 | $4.01 | $5.39 | -1.22% |
| Week 5 | $2.87 | $4.00 | $5.56 | -1.52% |
| Week 6 | $2.78 | $3.99 | $5.72 | -1.82% |
| Week 7 | $2.69 | $3.97 | $5.87 | -2.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Galectin Therapeutics Inc. is a clinical stage biopharmaceutical company that engages in drug development to create new therapies for fibrotic disease and cancer. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
The company has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc.
and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc. trades on the market as GALT. The current price is $4.33 with a market cap of $285.16M and a market rank of 3589. These figures place the stock within the broader healthcare sector and underscore its positioned market size.
The price outlook, as reflected in the provided forecasts, shows a neutral start in 2026 and a bullish trajectory through 2050, with substantial upside potential over the long term.
A major floor 72.1% below — a decisive break under it would weaken the trend.
The nearest floor, 42.6% below — buyers have tended to step in here.
The nearest ceiling, 22.9% above — a clean break opens room to run.
A major ceiling 58.9% above — clearing it would confirm fresh momentum.
Key GALT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GALT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.44 | Sell | $4.34 | Sell |
| MA 10 | $4.56 | Sell | $4.28 | Sell |
| MA 20 | $3.79 | Buy | $3.91 | Buy |
| MA 50 | $2.92 | Buy | $3.29 | Buy |
| MA 100 | $2.84 | Buy | $3.15 | Buy |
| MA 200 | $3.71 | Buy | $3.22 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.58 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 21.64 | Neutral |
| Williams %R (14) | -42.47 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 30.13 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 57.53 | Neutral |
| TRIX (15) | 2.52 | Buy |
| Awesome (5,34) | 1.18 | Buy |
| Ultimate (7,14,28) | 42.91 | Neutral |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 4.32 | Sell |
| ADX (14) | 33.57 | Buy |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is described as BULLISH, with RSI14 at 70. The stock is trading above both the SMA50 of $2.67 and the SMA200 of $3.71, indicating a positive near-term trend. Key levels include a support at $2.08 and a resistance at $4.99.
The 30-day price range spans from $2.86 to $6.57, and annualized volatility is 100%, highlighting notable price movement potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.08 | $4.06 | $6.22 | 0% | Neutral | |
| $5.35 | $7.37 | $10.99 | +82% | Bullish | |
| $5.99 | $8.78 | $13.94 | +116% | Bullish | |
| $5.63 | $8.68 | $14.47 | +114% | Bullish | |
| $6.60 | $10.68 | $18.53 | +163% | Bullish | |
| $6.66 | $11.25 | $20.22 | +177% | Bullish | |
| $6.71 | $11.83 | $21.92 | +191% | Bullish | |
| $9.30 | $17.07 | $32.50 | +320% | Bullish | |
| $11.84 | $22.61 | $44.14 | +457% | Bullish | |
| $13.12 | $26.05 | $52.03 | +542% | Bullish | |
| $17.85 | $39.67 | $87.08 | +877% | Bullish | |
| $37.28 | $82.85 | $190.56 | +19.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.08 | $4.06 | $5.12 | +0.00% |
| August 2026 | $3.35 | $4.06 | $5.12 | -0.07% |
| September 2026 | $3.18 | $3.90 | $5.02 | -3.84% |
| October 2026 | $3.41 | $4.24 | $5.56 | +8.80% |
| November 2026 | $3.66 | $4.60 | $6.12 | +8.48% |
| December 2026 | $3.64 | $4.62 | $6.22 | +0.33% |
Click any year to see its month-by-month GALT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GALT could reach as high as $6.22, with a base case around $4.06 and support toward $2.08 — roughly 0% from $4.06. A consolidation phase looks the most probable path here.
Expect GALT to range from $5.35 to $10.99 through 2027. The $7.37 average target implies a +82% move from current prices. That is up +82% on the projected 2026 average. Momentum favours further upside here.
The GALT price prediction for 2028 points to an average of $8.78 (low $5.99, high $13.94) — a potential gain of +116% on today's $4.06. Buyers look set to stay in control over this stretch.
In 2029, GALT is projected to trade between $5.63 and $14.47, averaging $8.68 — a potential gain of +114% from today's $4.06. That is -1% versus the projected 2028 average. Momentum favours further upside here.
Galectin Therapeutics Inc.'s 2030 outlook centres on $10.68, within a $6.60 to $18.53 range. That is up +23% on the projected 2029 average. That marks a +163% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GALT could reach as high as $20.22, with a base case around $11.25 and support toward $6.66 — roughly +177% from $4.06. Momentum favours further upside here.
Expect GALT to range from $6.71 to $21.92 through 2032. The $11.83 average target implies a +191% move from current prices. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The GALT price prediction for 2033 points to an average of $17.07 (low $9.30, high $32.50) — a potential gain of +320% on today's $4.06. Momentum favours further upside here.
In 2034, GALT is projected to trade between $11.84 and $44.14, averaging $22.61 — a potential gain of +457% from today's $4.06. That is up +32% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Galectin Therapeutics Inc.'s 2035 outlook centres on $26.05, within a $13.12 to $52.03 range. That is up +15% on the projected 2034 average. That marks a +542% change versus current levels. Momentum favours further upside here.
By 2040, GALT could reach as high as $87.08, with a base case around $39.67 and support toward $17.85 — roughly +877% from $4.06. Buyers look set to stay in control over this stretch.
Expect GALT to range from $37.28 to $190.56 through 2050. The $82.85 average target implies a +19.4x move from current prices. That is up +109% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GALT today (≈ 246.305419 GALT) could be worth
$20,406.8
+$19,406.8 (+1941%) by 2050 · US Dollar
Based on the average projected GALT price of $82.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GALTwould be worth at today's price.
$1,000 invested in GALT on Jul 10, 2025 (≈ 408.163257 GALT) would be worth
$1,657.14
+$657.14 (+65.7%) today · 1.66× · US Dollar
Based on a GALT entry price of $2.45 vs. today's $4.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.51 | $900.22 | -10.0% |
| 1 month ago | $2.38 | $1,705.88 | +70.6% |
| 3 months ago | $2.3 | $1,765.22 | +76.5% |
| 6 months ago | $3.16 | $1,284.81 | +28.5% |
| 1 year ago | $2.45 | $1,657.14 | +65.7% |
| All time (5.0y) ago | $2.8 | $1,450 | +45.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GALT forecast.
Our base-case forecast reaches $8.10 around 2028.
Implied market cap at $8.10: $533.44M
The multi-year forecast shows a bullish trajectory across the horizon. In 2026, the avg price is $4.33 with a min of $2.08 and a max of $6.77, and ROI of 0 with a NEUTRAL sentiment. By 2030, the avg climbs to $12.06 and the max to $20.95, with ROI of 178.5 and a bullish stance.
The path continues through 2033 ($20.46 avg, $372.6 ROI), 2034 ($26.04 avg, $501.3 ROI), and 2035 ($29.33 avg, $577.3 ROI). The long horizon shows 2040 with avg $46.81 and max $102.80 (ROI 981), and 2050 with avg $98.12 and max $225.67 (ROI 2166), all bearing a bullish sentiment. These are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
Avg $12.06, min $7.45, max $20.95, ROI 178.5%, sentiment BULLISH.
Forecasts show a neutral start in 2026, then a bullish outlook from 2027 onward with rising averages and ROIs up to 2166% by 2050; these are estimates and not guarantees.
Yes. The 2034 max forecast is $50.86, indicating the asset could reach around $50 in the mid-2030s per the forecast.
Current price is $4.33 and market cap is $285.16M.
2040: avg $46.81, max $102.80, ROI 981. 2050: avg $98.12, max $225.67, ROI 2166. Sentiment remains BULLISH.
Galectin Therapeutics Inc. Community Discussion
0Share your Galectin Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.